United States· US:0002-7669_161cb5e7-7955-45e5-bdde-9be94fdbe76a
CYRAMZA
A ramucirumab product containing ramucirumab, registered in United States by Eli Lilly and Company. The same ATC class is registered in 12 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Ramucirumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FG02 (ramucirumab), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 8 of them publish a price we can compare per daily dose
Ramucirumab · ATC L01FG02
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ramucirumab costs, country by country.
Normalised to the WHO defined daily dose (40 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ramucirumab · price per daily dose (40 mg)
USD · FX 28 Sept 2026
- CH Switzerland$200.15
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- RAMUCIRUMAB
- Manufacturer
- Eli Lilly and Company
- Country
- United States (US)
- ATC code
- L01FG02
- ATC class
- Ramucirumab
- Defined daily dose
- 40 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 1
- ndc110002-7669-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
141 interactions on record for ramucirumab.
Graded by severity as the source publishes them — 110 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ramucirumab · interactions on record
141 records
- 110 severe
- 31 moderate
Most severe, free to view
- DicoumarolB01AA01severe
- WarfarinB01AA03severe
- HeparinB01AB01severe
- Antithrombin IIIB01AB02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ramucirumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainCYRAMZA 10 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSIONEli Lilly Nederland B.V.
- United KingdomCyramza 100mg/10ml concentrate for solution for infusion vialsOriginalis B.V.
- CzechiaCYRAMZAEli Lilly Nederland B.V., Utrecht
- BelgiumCyramza 10 mg/mlEli Lilly Nederland
- SwitzerlandCyramza
- FinlandCyramzaEli Lilly Nederland B.V
- Japanラムシルマブ（遺伝子組換え）日本イーライリリー
- IrelandCyramza 10 mg/ml Concentrate for solution for infusionEli Lilly Nederland B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Cyramza
- Liechtenstein · Cyramza
- Norway · Cyramza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/633e7cf3-ddef-4ee9-8643-b62ec9ec3503 GET /v1/drugs/633e7cf3-ddef-4ee9-8643-b62ec9ec3503?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "10",
"substance": "RAMUCIRUMAB",
"productndc": "0002-7669",
"dosage_form": "SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "BLA125477",
"marketing_category": "BLA"
}See everything about ramucirumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.